… the first prospective randomized phase II trial to evaluate clinical efficacy of gefitinib or erlotinib
independently compared to a historical control as the second-line therapy in patients with …

… The primary objective of this study was to estimate the efficacy of erlotinib as a single agent
in patients with advanced biliary cancer. The choice of disease control as a primary end point …

… Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with
advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy …

… efficacy and safety profile of erlotinib compares with CT in … , randomized phase III study
comparing erlotinib with platinum-… 174 patients were randomly assigned to receive erlotinib or …

… Rationale for treatment and study design of tailor: a randomized phase III trial of second-line
erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell …

… Conclusion Erlotinib had minimal activity in unselected … patients who may derive benefit from
erlotinib treatment. … Patients began taking a daily oral dose of 150 mg erlotinib on study day …

… , randomized phase 1/2 study evaluated safety and efficacy of seribantumab plus erlotinib in
… Here, we report the activity of seribantumab plus erlotinib, versus erlotinib alone, in patients …

… patients were randomized to either dinaciclib or erlotinib using an adaptive Bayesian design
that adjusted the randomization … 2, patients who had progressed on erlotinib were permitted …

… This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus
erlotinib compared with erlotinib alone in patients with pretreated, nonsmall-cell lung cancer (…

… Our prospective, randomized phase II study of patients with NSCLC who previously … that
demonstrated entinostat combined with erlotinib enhances the effect of erlotinib alone and can …